How Platform Technologies Power Up Processes From Lab To cGMP

Versatile and scalable platform technologies empower efficient development and manufacturing of next-generation biotherapeutics by pushing the boundaries of expression system technology and process characterization, as well as ensuring complete user transparency. KBI Biopharma is positioned at the intersection of all three disciplines by virtue of its SUREtechnology Platform™ for mammalian cell line development, PUREplatform™ for microbial cell line development, and PROGRAMview™— a proprietary software that improves data access and collaboration among drug development program stakeholders.

KBI Biopharma experts Shaunak Uplekar, Ph.D., Associate Director of Upstream Process Development; Marlee Paulson, PROGRAMview Product Owner; and Erik Nordwald, Ph.D., Associate Director of Cell Line Development, recently discussed the efficacy and future potential of these initiatives. Following a webinar presentation that included several case studies, the speakers also answered a variety of participant questions covering the platform processes’ capabilities and their thoughtful implementation.